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Background: Rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are disorders that commonly
impact reproductive aged women.
Findings: Both women with RA and SLE have smaller sized families than do controls. In the case of RA
factors other than fertility contribute, while in women with SLE there may be diminished ovarian reserve due
to cyclophosphamide therapy and advanced maternal age. RA pregnancies can be complicated by preterm
birth and small-for-gestational aged infants. SLE pregnancies have higher rates of fetal loss, in particular in
those patients with co-existing antiphospholipid syndrome. SLE pregnancies are also more likely to be complicated by
pre-eclampsia and hypertension and to result in preterm birth and small-for-gestational aged infants.
Conclusion: Appropriate fertility evaluation and careful pregnancy planning with coordinated obstetrical care help
ensure better outcomes in these patient populations.
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The rheumatologic disorders systemic lupus erythemato-
sus (SLE) and rheumatoid arthritis (RA) have a clear
predilection for women. As such, issues regarding family
planning and pregnancy are an important part of the
management of these patients. Not only does pregnancy
itself cause physiologic and immunologic changes that
impact disease activity, but also women with SLE and
RA face the additional challenges of reduced fecundity
and worsened pregnancy outcomes. This article will re-
view the impact of these two common rheumatologic
disorders on fertility and pregnancy outcome.Fertility-related issues
Women with SLE and RA have smaller families than do
control groups [1]. The etiology appears to be multi-
factorial and may include disease activity, direct effect of
these disorders on fertility, medication exposure, and pa-
tient or physician preference (Table 1).* Correspondence: bbermas@partners.org
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stated.Rheumatoid arthritis family size
Women diagnosed with rheumatoid arthritis at an early
age have been shown to have fewer children than those di-
agnosed later in life. In one structured telephone interview
study of 411 women with RA, 8 % of women reported be-
ing advised to limit their family size, and 20 % reported
that their childbearing decisions were impacted by their
RA diagnosis [2]. While women with inflammatory ar-
thritides as a whole have been found to have higher rates
of nulliparity, a study that included 338 RA patients did
not find that these women were more likely to be nullipar-
ous than controls. Nonetheless, Wallenius et al. did find
that the mean number of children born to women with
RA was reduced in those diagnosed before 30 years of age
when compared with those diagnosed after age 30 [3],
suggesting that RA disease activity may impact family size.
Rheumatoid arthritis fertility
Other studies suggest that smaller family size predates
diagnosis of RA and so may relate to true alteration in fer-
tility: in one early report of 378 women with RA, fertility
was reduced prior to RA diagnosis [4]. In another study of
112 Danish patients, women with RA were slightly more
likely to have undergone fertility treatments and to have
greater time to pregnancy (>12 months) than were womeness This article is distributed under the terms of the Creative Commons
ativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution,
u give appropriate credit to the original author(s) and the source, provide a link
e if changes were made. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Table 3 Relative risk for adverse pregnancy outcomes in RA
and SLE
RA* SLE
Hypertension/preelampsia Possibly 20 %




C-section rate Increased Increased
SGA Yes Yes
Fetal/neonatal death No 17 %
Anti-Ro/SSA, Anti-La/ SSB
positive patients
Neonatal lupus 14–20 % 14–20 %




*RA patients are less commonly positive for anti-Ro/SS-A and anti-La/SS-B
antibodies than are patients with SLE, but when antibody-positive these patients
are subject to the same risk for neonatal lupus in their offspring
Table 1 Etiologies of reduced family size in RA and SLE
RA SLE
Delay in pursuing pregnancy Yes Yes
Medication Yes Yes
Diminished ovarian reserve No Yes–if
cyclophosphamide
exposed
Fetal/neonatal loss No Yes
Disease activity Yes Yes
Patient, physician, and psychosocial factors Yes Yes
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cent study of 245 female RA patients found that 64 of the
women had greater than a 12-month period of time to
pregnancy (TTP) and 40 of them did not conceive after
2 years: the resulting sub-fertility rate of 42 % was signifi-
cantly higher than that seen in the general population. In
this study factors associated with longer TTP were older
age, nulliparity, higher DAS28 score, prednisone dose
greater than 7.5 mg/day and NSAID use [6]. While
NSAIDs are known to impact both ovulation and implant-
ation in animals and may potentially do the same in
humans, the finding of higher prednisone doses related to
longer TTP is novel and bears further exploration to deter-
mine whether this reflects medication effect, increased dis-
ease activity, or other variables. Other factors such as prior
contraceptive methods and partner-related determinants
were not studied in this cohort.
Rheumatoid arthritis ovarian function
Whether the increased time to pregnancy represents
decreased ovarian function is an important question.
Anti-Müllerian hormone (AMH), produced by ovarian
granulosa cells, is a well-established marker of ovarian
reserve. A recent report found that AMH levels in 19
women with childhood-onset SLE who had been treated
with methotrexate were below normal [7]. Given that
methotrexate is the cornerstone of therapy for rheumatoid
arthritis, this raises concern that this common RA treat-
ment could negatively impact ovarian reserve. Reassur-
ingly, however, a study by Brower et al. examined AMH
levels in 72 recently diagnosed RA patients compared to
409 healthy controls, and showed no reduction in AMH
levels overall, including AMH levels in the 31 patientsTable 2 Methods for fertility preservation in SLE patients
receiving cyclophosphomide
Limiting cytotoxic agent exposure especially in women > age 30
GnRH agonists during cyclophosphamide therapy
Cryopreservation of oocytes or embryos (time delay is problematic as
there is usually an urgent need for treatment)
Ovarian tissue cryopreservation (research technique only at this time)who had received methotrexate [8]. Whether these differ-
ences reflect patients age is unclear, as the mean age of the
SLE patients was 16 years, compared with a mean age of
the RA patients of 35 years. Alternatively, this may reflect
differing impacts of the different underlying diseases on
fertility. Thus, while women with RA do have smaller
family sizes and longer times to pregnancy, ovarian reserve
as measured by AMH does not appear to be significantly
compromised.Systemic lupus erythematosus fertility
Fertility in stable systemic lupus erythematosus (SLE)
patients is largely unaffected by the diagnosis of lupus it-
self. As with women with RA, female SLE patients have
a smaller average family size that is likely related to in-
direct disease-related factors such as psychosocial effects
as well as use of cytotoxic medications for severe SLE
manifestations [9]. Decreased fertility in SLE may result
from medication effects, disease flare, disease-related
damage, or advanced age. Use of cyclophosphamide (CYC)
accounts for most non-age related infertility in SLE pa-
tients, although the increasing use of mycophenolate
mofetil for lupus nephritis may reduce this incidence.
Risk of CYC-related infertility is associated with both
the cumulative dose as well as the age at which the
drug is administered. Likelihood of maintaining fertility
after treatment is greatest for those patients with age
less than 30 years, six or fewer monthly intravenous
pulses, cumulative dose less than 7 g, and lack of amen-
norhea before or during drug administration [10]. Other
lupus medications are less likely to have a significant im-
pact on fertility, although non-steroidal anti-inflammatory
drugs (NSAIDs) have been suggested as a potential con-
tributor to infertility and high-dose corticosteroids are
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through their effect on the hypothalamic-pituitary axis
(HPA).
SLE ovarian reserve
Preliminary work suggests that SLE patients may have
menstrual disturbances or even amenorrhea as a result of
very active disease [11]. In addition, AMH serum levels
have been reported to be lower in a group of 33 non-CYC
treated SLE patients compared with 33 age-matched con-
trols [12]. Importantly, lupus glomerulonephritis-induced
renal insufficiency or failure may lead to hypofertility or
infertility through a disruption of the HPA, which may re-
verse with renal transplantation.
SLE autoantibodies
Although data are limited, autoantibody profile does not
appear to impact fertility in women with SLE. While as-
sessment for antiphospholipid antibodies (aPL) in women
with lupus and other connective tissue diseases (CTD) is
critical in predicting risk for adverse pregnancy outcome,
recent controlled studies do not support an association
between aPL and infertility or poor in-vitro fertilization
(IVF) outcome despite early reports to the contrary. At
this time, assessment or treatment for aPL in infertile
women is not recommended [13].
Other factors
Advanced age is a significant factor for infertility in
many SLE patients, as it is in the general population.
Onset of SLE is often during the early reproductive years
and patients are generally counseled to avoid pregnancy
when disease is active. Since female fertility declines
with advancing age due to progressive loss of ovarian re-
serve, many SLE patients are older when they attempt to
conceive and may encounter age-related difficulties.
While premature ovarian failure (persistent amenorrhea
with elevated follicle stimulating hormone level prior to
age 40) may occur as a result of autoimmune etiology in
the general population, it is rarely associated with sys-
temic autoimmune diseases such as SLE [14].
SLE fertility preservation
Preservation of fertility in female SLE patients focuses
on limiting use of cytotoxic medications when feasible
and protecting the ovaries throughout cytotoxic therapy;
however, the need for prompt and effective therapy for
severe disease often takes precedence (Table 2). Cryo-
preservation of either oocytes or embryos is an effective
option for preservation of fertility but requires ovarian
stimulation, which may be impractical given the usual
need to institute therapy quickly to prevent damage, as
well as the risk of hyperstimulation in an already active
SLE patient. The patient’s age at which CYC isadministered is not amenable to change, but an effort
should be made to minimize the total CYC dose. The use
of the Euro-Lupus CYC regimen, which provides less
overall CYC exposure, or CYC alternatives such as myco-
phenolate mofetil may be considered if appropriate. Treat-
ment with gonadotrophic hormone receptor (GnRH)
agonists during CYC therapy to minimize ovarian toxicity
has become common practice, although the degree of
benefit associated with this therapy is still being defined.
The traditional measure of infertility after CYC has been
the development of clinical amenorrhea, but newer object-
ive measures such as AMH levels should provide a better
assessment of ovarian reserve in future studies. In a study
of 20 SLE patients who received GnRH-agonist leuprolide
at 10–14 days prior to CYC pulse therapy there was an es-
timated 68 % increase in preserved ovarian function com-
pared to 20 SLE patients who had not received this
therapy [15, 16]. GnRH-agonist therapy should not be ad-
ministered immediately before CYC: when given during
the follicular phase of the cycle, it can stimulate the ovar-
ies and worsen ovarian damage [17]. Patients who do not
receive GnRH-agonist therapy prior to their first infusion
can begin treatment after the first cycle and be treated at
monthly intervals thereafter.
Preservation of fertility though cryopreservation tech-
niques is not possible when administration of cyclophos-
phamide is deemed urgent. Ovarian hyperstimulation
and oocyte retrieval necessitate a 2-week time delay in
lupus treatment. However, oocyte cryopreservation is be-
coming increasingly popular in the general population as
women pursue oocyte freezing for fertility preservation
in anticipation of future IVF. This approach may be con-
sidered for stable inactive SLE patients concerned about
age-related infertility.
Ovarian tissue cryopreservation remains primarily a
research procedure at this time but improved techniques
in the future could make this an ideal method for fertil-
ity preservation in SLE patients requiring CYC therapy.
Ovarian tissue is removed through laparoscopic oophor-
ectomy without need for ovarian stimulation. Oocytes
are either matured in vitro and frozen, or the ovarian
tissue is frozen in thin strips for later oocyte maturation or
auto-transplantation [18]. An alternative option for preg-
nancy in women with few or poor quality oocytes (whether
due to cytotoxic therapy, age, or other etiology) is the use
of donor eggs. IVF utilizing a donor oocyte and partner’s
sperm may be performed during a period of quiescent dis-
ease and provides an alternative option for pregnancy.
SLE and assisted reproduction techniques
Assisted reproduction techniques (ART), including ovar-
ian induction (OI) with or without in vitro fertilization
(IVF) and embryo transfer, may be performed in patients
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Ovarian hyperstimulation syndrome (OHSS) is an im-
portant complication of IVF resulting in a diffuse capil-
lary leak syndrome with pleural effusion and ascites.
Severe OHSS is a rare but important cause of throm-
bosis and renal compromise in IVF patients, issues of
potential relevance for SLE patients.
The controlled ovarian hyperstimulation necessary
for IVF may increase the risk of lupus flare and/or
thrombosis in patients with SLE and/or antiphospholi-
pid syndrome (APS) and risk appears to be related to
degree of elevation in 17β-estradiol levels. However,
despite individual case reports describing flare and
thrombosis in SLE and/or APS patients [14], large
series report overall positive outcomes in a combined
total of 177 OI and IVF cycles [18, 19]. Flare, occurring
in 21–42 % patients, was generally mild and responsive
to therapy. Risk of both lupus flare and thrombosis was
greater if the diagnosis of SLE was not known at the
start of the cycle [19]. Thrombosis was rare, although
almost all patients with positive aPL or known APS
were treated empirically throughout the cycle with as-
pirin and/or heparin.
Options to minimize thrombotic risk for patients with
SLE and aPL during IVF procedures primarily involve
modulation of the procedure to avoid very high estrogen
levels [14]. Prophylactic aspirin and/or heparin therapy
for patients with positive aPL is recommended, given the
likely increase in thrombosis risk and the absence of
data-derived guidelines. Patients with APS on warfarin
should switch to therapeutic heparin or low molecular
weight heparin prior to the start of the cycle and hold it
24 h before the oocyte retrieval process, which requires
transvaginal puncture [14].
Prophylactic corticosteroid through IVF cycles is not
generally recommended but patients should be closely
observed for symptoms of flare and treated promptly
if necessary. Assisted reproductive techniques should
only be performed in lupus patients who have stable
inactive disease on pregnancy safe medications, i.e.
those who would otherwise be considered safe to
undertake pregnancy. Rarely, a patient may be consid-
ered suitable for IVF but not pregnancy, for example,
those with severe lupus damage such as significant
renal insufficiency. Such patients may tolerate ovarian
hyperstimulation but not the hemodynamic stress of
pregnancy. IVF followed by embryo transfer to a gesta-
tional carrier can result in a biological child for these
patients.
Addressing fertility issues in SLE patients requires a
high degree of collaboration between the reproductive
medicine specialist, high-risk obstetrician, and rheuma-
tologist. This collaboration maximizes the potential for a
successful outcome while minimizing maternal risk.Pregnancy outcomes
Rheumatoid arthritis
Pregnancy outcomes in RA are overall good, with minor
differences when compared to the general population
(Table 3).
Pregnancy loss in RA
Early miscarriage (pregnancy loss <10 weeks gestation)
is common in the general population, whereas fetal loss
(≥10 weeks gestation) and stillbirth (loss ≥20 weeks of
gestation) are not. There are limited retrospective data
on risk of miscarriage in women with rheumatoid arth-
ritis. One small study of 40 women with RA did not re-
veal an increase in miscarriage rate among women with
RA [20]. In another study of 195 women with RA, no in-
creased rate of spontaneous abortion was seen although
a non-significant increase in stillbirth was reported [21].
One retrospective questionnaire study of 113 female RA
patients found that miscarriage history prior to RA may
portend worse radiographic disease progression. While
these results are intriguing, they are limited by question-
naire data collection and recall bias [22].
RA and preeclampsia
RA pregnancies may have higher rates of maternal hyper-
tension and preeclampsia. Using obstetrical hospitalization
claims in the United States, univariate analysis of 1425 de-
liveries to RA mothers revealed higher rates of hyperten-
sion in patients when compared to controls; however, this
was no longer significant in multivariate analysis once ma-
ternal age was taken into account [23]. Data on 1912
women with RA from the Taiwan national health insur-
ance database showed an odds ratio of 2.22 (95 % CI 1.59
to 3.11) for the development of preeclampsia when com-
pared with controls [24]. Information regarding disease
activity and medication use was not available. In contrast,
in a smaller study of 133 RA pregnancies, no cases of pre-
eclampsia were reported although there were five admis-
sions for hypertension, a finding that was not statistically
significant [25].
Preterm birth and other pregnancy complications in RA
Preterm birth is more likely in RA pregnancies. In a
study of 243 women with rheumatoid arthritis, the ad-
justed odds ratio for prematurity was 1.78 (95 % CI 1.21
to 2.60) when compared to control pregnancies [26].
Another report of 46 pregnancies in 40 patients with RA
found that 28 % of women delivered prior to 37 weeks.
While prematurity was not significantly associated with
disease activity in this study, it was associated with dis-
continuation of medications [27]. The odds ratio for pre-
maturity was 1.48 (95 % CI 1.20 to 1.84) in a Danish
registry that included 2101 children born to mothers
with RA. Interestingly, women who subsequently went
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CI 1.07 to 1.64) for preterm birth, suggesting that preg-
nancy issues may pre-date diagnosis [28].
Low birth weight and small-for-gestational aged (SGA)
infants are also reported in RA pregnancies. In the large
cohort of 1912 Taiwanese patients, the odds ratio for
low birth weight was 1.47 (95 % CI 1.22 to 1.78) and for
SGA infants it was 1.2 (95 % CI 1.05 to 1.38) [24]. Mean
birth weight for infants of RA mothers was 87 g lower
than that for control infants in Rom et al.’s Danish co-
hort of 2101 children, although when adjusted for gesta-
tional age the difference was less (62 g). Likewise, in a
Norwegian registry of 128 first pregnancies in women
with inflammatory arthritidies, lower birth weight was re-
ported among offspring of women with RA [29]. This
study also reported a higher Cesarean-section (C/S) rate
in RA pregnancies, although almost all of these proce-
dures were elective, underscoring the importance of
understanding patient and physician preference in meas-
uring this particular pregnancy outcome.
While less dramatic than the disease effect on preg-
nancy outcome for SLE pregnancies (detailed below), RA
pregnancies are nevertheless associated with higher rates
of preeclampsia, low birth weight, prematurity and SGA
infants. Higher elective C/S rates have also been shown in
RA pregnancies and in some cases, may relate to concern
for limited range of motion of disease-affected or pros-
thetic hip joints.Systemic lupus erythematosus
While pregnancy outcome for women with lupus has
improved, SLE pregnancies are still associated with a
higher risk of complications than are pregnancies in
healthy women. Maternal morbidity and mortality as
well as higher rates of poor fetal outcomes are issues of
concern for these patients (Table 3).SLE maternal morbidity
In one large study of 13,555 pregnancies that utilized in-
surance claims data, maternal mortality was 20-fold higher
among women with SLE [30]; in addition, this analysis
demonstrated a 3–7 fold increased risk of thrombosis, in-
fection and thrombocytopenia during pregnancy for
women with SLE. Higher rates of C/S, preterm labor and
preeclampsia were also reported. Increased rates of hyper-
tension, C/S, and venous thromboembolism were similarly
reported in a California study of 555 lupus pregnancies
[31]. Preeclampsia is more common in SLE and occurs in
up to 20 % of lupus pregnancies; active disease (particu-
larly nephritis) appears to contribute to this increased risk
[32, 33]. Any history of nephritis, whether in the precon-
ception or conception period, predisposes to preeclampsia
[34]. Antiphospholipid antibodies are also suggested tocontribute to preeclampsia risk, with some but not all data
supporting this association [35].SLE and preeclampsia
Preeclampsia may be difficult to distinguish from lupus
flare, presenting one of the more significant clinical chal-
lenges in the management of SLE patients during preg-
nancy. Hypertension with renal abnormalities due to SLE
flare is suggested by onset before 20 weeks of gestation,
lowered complement levels, increased ds DNA titers and
active urine sediment; later onset of symptoms, increased
uric acid concentration, bland urine sediment and increas-
ing liver function tests are more suggestive of preeclamp-
sia. Distinguishing between these two entities when
possible is important: preeclampsia is managed with ex-
pectant delivery, while SLE flare is treated with immuno-
suppression. When both occur together, or when it is not
possible to distinguish, patients should be treated for both.Pregnancy loss in SLE
Pregnancy loss rates are clearly increased in patients with
SLE and are estimated at 15–30 % although this figure has
improved in recent years. Clarke et al. compared their
current cohort of 83 pregnancies to historical data and
found the pregnancy loss rate decreased from 40 to 17 %
over 40 years [36]. Higher disease activity in the first or
second trimester contributes to a three-fold higher rate of
pregnancy loss as compared to pregnancies in which dis-
ease is well controlled [37]. Factors that increase risk for
fetal loss and stillbirth in SLE include high levels of disease
activity before and during pregnancy, presence of aPL
(particularly lupus anticoagulant), lupus nephritis, renal
insufficiency, and hypertension [37–40].
APL have an important effect on pregnancy outcome
in SLE patients. While close to one-third of lupus pa-
tients are positive for aPL, far fewer meet the criteria to
be diagnosed with obstetrical antiphospholipid antibody
syndrome (OB-APS). Criteria for OB-APS include three
or more early (<10 weeks) pregnancy losses, fetal loss or
stillbirth, or delivery at less than 34 weeks in women
who have documented persistent aPL whether lupus
anticoagulant (LAC), high titer IgG or IgM anticardioli-
pin (aCL) or high titer IgG or IgM anti-β2 Glycoprotein I
(aβ2GPI) [41]. LAC, aCL and aβ2GPI are all considered to
be potentially pathologic, although LAC appears to carry
the highest risk for clinical complications: LAC is the most
powerful predictor for adverse pregnancy outcome in
aPL-positive patients [42]. Other non-criteria antipho-
spholipid antibodies such as anti-phosphatidylserine or
others have not been studied in a controlled manner but
have been suggested to be associated with pregnancy loss.
Such non-criteria antibodies rarely occur in the absence of
classic aPL, however [43].
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Preterm birth and intrauterine growth restriction are
clearly increased in patients with SLE. In one meta-
analysis of 2751 lupus pregnancies, 40 % of patients were
delivered prior to 37 weeks [44]. Other studies have sub-
stantiated this finding, reporting similar preterm birth
rates [45, 46]. Preterm birth can occur because of pre-
term premature rupture of membranes (PPROM), pre-
mature labor, or may be iatrogenic, as when severe lupus
flare or fetal distress trigger induction of labor. Risk fac-
tors for PPROM include treatment with glucocorticoids
or immunosuppressive therapy as well as presence of
aPL, renal disease or hypertension [47].
SGA infants appear to be more common in SLE preg-
nancy, especially in the setting of positive aPL and
hypertension. As in RA, rates for C/S delivery are also
significantly increased [46]; however, when reviewing the
available literature, it is difficult to discriminate between
C/S deliveries due to patient and physician preferences
versus those necessitated by fetal distress or other med-
ical indication.
Neonatal lupus
Anti-Ro/SS-A and anti-La/SS-B antibodies are present in
about one-quarter to one-third of women with SLE, in
particular those with secondary Sjogren’s syndrome. These
antibodies carry a 14–20 % risk for neonatal lupus affect-
ing the infant. Neonatal lupus may include skin rash, cyto-
penias and hepatic abnormalities; these findings generally
resolve by 6 months post-partum. However, 2 % of off-
spring of antibody-positive women develop congenital
complete heart block (CCHB) and generally require a per-
manent pacemaker. Rarely, other cardiac anomalies occur
that can result in fetal or neonatal death. The recurrence
rate of CCHB in a subsequent pregnancy is roughly 17 %.
Women who are antibody positive should be monitored
with fetal ultrasounds between weeks 16 and 34 of gesta-
tion. Recommendations regarding the frequency of screen-
ing (weekly, biweekly, monthly) vary [48]. While treatment
with dexamethosone and IVIG have been used on a case by
case basis as heart block evolves, neither of these therapies
have been proven successful [48–50]. There is growing evi-
dence that maintaining women on hydroxychloroquine
throughout pregnancy may reduce the recurrence rate of
CCHB [51], and prospective studies are underway.
While SLE pregnancies have higher rates of pregnancy
loss, intrauterine growth restriction, prematurity and C/S,
the majority of women with SLE can anticipate a success-
ful pregnancy, especially with appropriate pre-pregnancy
planning.
Pregnancy management
While a comprehensive review of management is beyond
the scope of this article, there are certain basic tenetsthat apply to all rheumatic disease pregnancies. Whether
RA or SLE, disease should be in remission on medica-
tions compatible with pregnancy prior to conception.
Patients should have an obstetrician familiar with the
management of these disorders during pregnancy, usu-
ally a maternal-fetal medicine specialist. Likewise, the
rheumatologist managing these patients should have at
least a basic knowledge of disease course during preg-
nancy, relevant risk factors, and potential toxicities of
anti-rheumatic drugs. Finally, patients should be counseled
and educated regarding their individual risk profile for ad-
verse outcomes, both maternal and fetal/neonatal.
Conclusion
Rheumatoid arthritis and systemic lupus erythematosus
are disorders that affect women during the childbearing
years. Both disorders may impact ultimate family size for
multiple reasons; however, ovarian function is preserved
in RA patients, while medication use and severe disease
activity or damage may impair fertility in SLE patients.
Both RA and SLE pregnancies are associated with higher
rates of preterm delivery, C/S rate and SGA infants al-
though rates are higher in SLE women. SLE pregnancies
are also more likely to be complicated by pregnancy loss
and preeclampsia, in particular in those women who
have aPL or renal disease. Women with SLE who have
the anti-Ro/SS-A and anti-La/SS-B antibodies are at risk
of neonatal lupus, including CCHB, in their offspring.
Careful planning and a team approach permit most
women with RA and SLE to have successful pregnancies.
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